Advisory Board April 1, 2024

There is a lot to be excited about in the new era of drugs, but there is a lot to be anxious about too, including high costs and impending legislation. Radio Advisory’s Rachel Woods sat down with Advisory Board experts Rachael Peroutky and Chloe Bakst to discuss how the industry should be thinking about this new era of drugs, and why healthcare organizations can’t afford to sit around today and strategize later.

Below is a summary of key takeaways from the interview. Download the Radio Advisory episode for the full conversation.

Ready-to-use slides: How to navigate the evolving high-cost drug landscape

Challenges and opportunities in the drug space

The drug space is experiencing significant changes, including the introduction of high-cost...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Pharma, Pharma / Biotech, Trends
Aviv Regev: The Revolution in Digital Biology
Global Inequities In Access To Drugs Costs Millions Of Lives Each Year
STAT+: New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition
FDA Update for Week of April 22, 2024: Second Gene Therapy for Hemophilia B
Why Conflicts Of Interest May Not Be As Bad As You Think (And Besides We All Have Them!)

Share This Article